The inhibition of PYGL and G6PD did not substantially affect the cell viability of KU812 ImaR cells more, but it decreased the cell viability of both KU812 P and ImaR cells which open new avenues to be considered in drug repurposing for CML. Here, G6PD is linked to chronic myelogenous leukemia, BCR-ABL1 positive.